Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy.
Identifieur interne : 001708 ( PubMed/Curation ); précédent : 001707; suivant : 001709Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy.
Auteurs : Hiroshi Nagayama [Japon] ; Masayuki Ueda ; Mineo Yamazaki ; Yasuhiro Nishiyama ; Makoto Hamamoto ; Yasuo KatayamaSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2010.
English descriptors
- KwdEn :
- 3-Iodobenzylguanidine (diagnostic use), Aged, Female, Heart (radionuclide imaging), Humans, Iodine Radioisotopes (diagnostic use), Longitudinal Studies, Male, Middle Aged, Multiple System Atrophy (diagnosis), Multiple System Atrophy (radionuclide imaging), Myocardial Perfusion Imaging (methods), Radiopharmaceuticals (diagnostic use), Retrospective Studies, Statistics, Nonparametric, Time Factors.
- MESH :
- chemical , diagnostic use : 3-Iodobenzylguanidine, Iodine Radioisotopes, Radiopharmaceuticals.
- diagnosis : Multiple System Atrophy.
- methods : Myocardial Perfusion Imaging.
- radionuclide imaging : Heart, Multiple System Atrophy.
- Aged, Female, Humans, Longitudinal Studies, Male, Middle Aged, Retrospective Studies, Statistics, Nonparametric, Time Factors.
Abstract
[(123)I]-Meta-iodobenzylguanidine (MIBG) myocardial scintigraphy is useful for distinguishing multiple system atrophy (MSA) from Parkinson disease. In this study, longitudinal observation using MIBG myocardial scintigraphy was carried out in patients with MSA to evaluate the association of myocardial MIBG uptake with clinical features. A total of 96 MIBG examinations were performed in 52 patients with MSA. The heart/mediastinum (H/M) ratio of MIBG uptake at 240 minutes after injection was below the lower limit in 16 patients with MSA (31.3%). Overall, the H/M ratio correlated with neither disease duration nor severity. In the follow-up observations, the H/M ratio did not show any specific trends, in contrast with the continuous decrease observed in patients with Parkinson's disease. This data clearly showed that cardiac MIBG uptake cannot necessarily be preserved in patients with MSA and that approximately 30% of patients with MSA showed decreased MIBG uptake without any correlation to disease duration or severity.
DOI: 10.1002/mds.23338
PubMed: 20645402
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001708
Links to Exploration step
pubmed:20645402Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy.</title><author><name sortKey="Nagayama, Hiroshi" sort="Nagayama, Hiroshi" uniqKey="Nagayama H" first="Hiroshi" last="Nagayama">Hiroshi Nagayama</name><affiliation wicri:level="1"><nlm:affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Sendagi Bunkyo-ku, Tokyo, Japan. nagayama@nms.ac.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Sendagi Bunkyo-ku, Tokyo</wicri:regionArea></affiliation></author><author><name sortKey="Ueda, Masayuki" sort="Ueda, Masayuki" uniqKey="Ueda M" first="Masayuki" last="Ueda">Masayuki Ueda</name></author><author><name sortKey="Yamazaki, Mineo" sort="Yamazaki, Mineo" uniqKey="Yamazaki M" first="Mineo" last="Yamazaki">Mineo Yamazaki</name></author><author><name sortKey="Nishiyama, Yasuhiro" sort="Nishiyama, Yasuhiro" uniqKey="Nishiyama Y" first="Yasuhiro" last="Nishiyama">Yasuhiro Nishiyama</name></author><author><name sortKey="Hamamoto, Makoto" sort="Hamamoto, Makoto" uniqKey="Hamamoto M" first="Makoto" last="Hamamoto">Makoto Hamamoto</name></author><author><name sortKey="Katayama, Yasuo" sort="Katayama, Yasuo" uniqKey="Katayama Y" first="Yasuo" last="Katayama">Yasuo Katayama</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="doi">10.1002/mds.23338</idno><idno type="RBID">pubmed:20645402</idno><idno type="pmid">20645402</idno><idno type="wicri:Area/PubMed/Corpus">001708</idno><idno type="wicri:Area/PubMed/Curation">001708</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy.</title><author><name sortKey="Nagayama, Hiroshi" sort="Nagayama, Hiroshi" uniqKey="Nagayama H" first="Hiroshi" last="Nagayama">Hiroshi Nagayama</name><affiliation wicri:level="1"><nlm:affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Sendagi Bunkyo-ku, Tokyo, Japan. nagayama@nms.ac.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Sendagi Bunkyo-ku, Tokyo</wicri:regionArea></affiliation></author><author><name sortKey="Ueda, Masayuki" sort="Ueda, Masayuki" uniqKey="Ueda M" first="Masayuki" last="Ueda">Masayuki Ueda</name></author><author><name sortKey="Yamazaki, Mineo" sort="Yamazaki, Mineo" uniqKey="Yamazaki M" first="Mineo" last="Yamazaki">Mineo Yamazaki</name></author><author><name sortKey="Nishiyama, Yasuhiro" sort="Nishiyama, Yasuhiro" uniqKey="Nishiyama Y" first="Yasuhiro" last="Nishiyama">Yasuhiro Nishiyama</name></author><author><name sortKey="Hamamoto, Makoto" sort="Hamamoto, Makoto" uniqKey="Hamamoto M" first="Makoto" last="Hamamoto">Makoto Hamamoto</name></author><author><name sortKey="Katayama, Yasuo" sort="Katayama, Yasuo" uniqKey="Katayama Y" first="Yasuo" last="Katayama">Yasuo Katayama</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3-Iodobenzylguanidine (diagnostic use)</term><term>Aged</term><term>Female</term><term>Heart (radionuclide imaging)</term><term>Humans</term><term>Iodine Radioisotopes (diagnostic use)</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Multiple System Atrophy (diagnosis)</term><term>Multiple System Atrophy (radionuclide imaging)</term><term>Myocardial Perfusion Imaging (methods)</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Retrospective Studies</term><term>Statistics, Nonparametric</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>3-Iodobenzylguanidine</term><term>Iodine Radioisotopes</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Multiple System Atrophy</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Myocardial Perfusion Imaging</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Heart</term><term>Multiple System Atrophy</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Statistics, Nonparametric</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">[(123)I]-Meta-iodobenzylguanidine (MIBG) myocardial scintigraphy is useful for distinguishing multiple system atrophy (MSA) from Parkinson disease. In this study, longitudinal observation using MIBG myocardial scintigraphy was carried out in patients with MSA to evaluate the association of myocardial MIBG uptake with clinical features. A total of 96 MIBG examinations were performed in 52 patients with MSA. The heart/mediastinum (H/M) ratio of MIBG uptake at 240 minutes after injection was below the lower limit in 16 patients with MSA (31.3%). Overall, the H/M ratio correlated with neither disease duration nor severity. In the follow-up observations, the H/M ratio did not show any specific trends, in contrast with the continuous decrease observed in patients with Parkinson's disease. This data clearly showed that cardiac MIBG uptake cannot necessarily be preserved in patients with MSA and that approximately 30% of patients with MSA showed decreased MIBG uptake without any correlation to disease duration or severity.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20645402</PMID><DateCreated><Year>2010</Year><Month>08</Month><Day>26</Day></DateCreated><DateCompleted><Year>2010</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy.</ArticleTitle><Pagination><MedlinePgn>1744-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.23338</ELocationID><Abstract><AbstractText>[(123)I]-Meta-iodobenzylguanidine (MIBG) myocardial scintigraphy is useful for distinguishing multiple system atrophy (MSA) from Parkinson disease. In this study, longitudinal observation using MIBG myocardial scintigraphy was carried out in patients with MSA to evaluate the association of myocardial MIBG uptake with clinical features. A total of 96 MIBG examinations were performed in 52 patients with MSA. The heart/mediastinum (H/M) ratio of MIBG uptake at 240 minutes after injection was below the lower limit in 16 patients with MSA (31.3%). Overall, the H/M ratio correlated with neither disease duration nor severity. In the follow-up observations, the H/M ratio did not show any specific trends, in contrast with the continuous decrease observed in patients with Parkinson's disease. This data clearly showed that cardiac MIBG uptake cannot necessarily be preserved in patients with MSA and that approximately 30% of patients with MSA showed decreased MIBG uptake without any correlation to disease duration or severity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nagayama</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Divisions of Neurology, Nephrology, and Rheumatology, Department of Internal Medicine, Nippon Medical School, Sendagi Bunkyo-ku, Tokyo, Japan. nagayama@nms.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueda</LastName><ForeName>Masayuki</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yamazaki</LastName><ForeName>Mineo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nishiyama</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Hamamoto</LastName><ForeName>Makoto</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Katayama</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>35MRW7B4AD</RegistryNumber><NameOfSubstance UI="D019797">3-Iodobenzylguanidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019797">3-Iodobenzylguanidine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006321">Heart</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007457">Iodine Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008137">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019578">Multiple System Atrophy</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D055414">Myocardial Perfusion Imaging</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019275">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018709">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23338</ArticleId><ArticleId IdType="pubmed">20645402</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001708 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001708 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:20645402
|texte= Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:20645402" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |